SCHEMBL23091169

SCHEMBL23091169

COc1cc(-c2ccc(C(=O)Nc3cccnc3)o2)ccc1O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 7/20 0.64
▸ RAB9A P51151 6/20 0.64
▸ MAPK1 P28482 4/20 0.64
▸ POLB P06746 2/20 0.64
▸ MAPT P10636 7/20 0.61
▸ SMN1; SMN2 Q16637 7/20 0.61
▸ KDM4E B2RXH2 4/20 0.61
▸ ALDH1A1 P00352 4/20 0.61
▸ HSD17B10 Q99714 2/20 0.61
▸ USP2 O75604 2/20 0.61
▸ TP53 P04637 2/20 0.60
▸ HPGD P15428 4/20 0.54
▸ CYP1A2 P05177 2/20 0.54
▸ CYP3A4 P08684 2/20 0.54
▸ CYP2D6 P10635 2/20 0.54
▸ CYP2C9 P11712 2/20 0.54
▸ CYP2C19 P33261 2/20 0.54
▸ LMNA P02545 3/20 0.53
▸ TSHR P16473 1/20 0.51
▸ GAA P10253 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30501668 1.00 NPC1 (0.64) NPC1RAB9AMAPK1POLBMAPT
SCHEMBL23091188 0.91 RAB9A (0.72) NPC1RAB9AMAPK1POLBMAPT
SCHEMBL30501738 0.87 PTPN1 (0.61) NPC1RAB9AMAPK1POLBMAPT
SCHEMBL23091179 0.87 PTPN1 (0.61) NPC1RAB9AMAPK1POLBMAPT
SCHEMBL23091167 0.81 NPC1 (0.67) NPC1RAB9AMAPK1POLBMAPT
SCHEMBL30501715 0.80 NPC1 (0.77) NPC1RAB9AMAPK1POLBMAPT
SCHEMBL23091224 0.80 NPC1 (0.77) NPC1RAB9AMAPK1POLBMAPT
SCHEMBL23091241 0.80 RAB9A (0.69) NPC1RAB9AMAPK1POLBMAPT
SCHEMBL23091237 0.78 NPC1 (0.54) NPC1RAB9APOLBMAPTSMN1; SMN2
SCHEMBL30501657 0.78 NPC1 (0.54) NPC1RAB9APOLBMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3805210-B1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AUTOPHAGYSCIENCES INC (KR) 2023-11-29 — — EP claimed
CN-112004807-B Compounds and pharmaceutical compositions comprising the same 自体吞噬科学有限公司 2023-07-18 — — CN claimed
US-11407744-B2 Compound and pharmaceutical composition comprising same Autophagysciences Inc. (KR) 2022-08-09 — — US claimed
EP-3805210-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Autophagysciences, Inc (KR) 2021-04-14 — — EP claimed
US-20210078987-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Autophagysciences Inc. (KR) 2021-03-18 — — US claimed
EP-3805210-B1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AUTOPHAGYSCIENCES INC (KR) 2023-11-29 — — EP disclosed
EP-3805210-B1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AUTOPHAGYSCIENCES INC (KR) 2023-11-29 — — EP disclosed
CN-112004807-B Compounds and pharmaceutical compositions comprising the same 自体吞噬科学有限公司 2023-07-18 — — CN disclosed
US-11407744-B2 Compound and pharmaceutical composition comprising same Autophagysciences Inc. (KR) 2022-08-09 — — US disclosed
EP-3805210-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Autophagysciences, Inc (KR) 2021-04-14 — — EP disclosed
EP-3805210-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Autophagysciences, Inc (KR) 2021-04-14 — — EP disclosed
US-20210078987-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Autophagysciences Inc. (KR) 2021-03-18 — — US disclosed
US-20210078987-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Autophagysciences Inc. (KR) 2021-03-18 — — US disclosed
CN-112004807-A Novel compounds and pharmaceutical compositions comprising said compounds 自体吞噬科学有限公司 2020-11-27 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11407744-B2 Compound and pharmaceutical composition comprising same TFEB, ATG7, BECN1 NPC1 24/4885RAB9A 248/4885MAPK1 2111/4885
US-20210078987-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME TFEB, ATG7, BECN1 NPC1 25/4885RAB9A 194/4885MAPK1 2110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback